Online Program

Urinary soy isoflavone excretion is associated with favorable cardiometabolic risk markers in pregnant US women: Nhanes, 2001-2008

Monday, November 4, 2013

Ling Shi, PhD, College of Nursing and Health Sciences, University of Massachusetts Boston, Boston, MA
Alice Lichtenstein, DSc, Tufts University Friedman School of Nutrition Science and Policy, Boston, MA
Emily Jones, Nursing, University of Massachusetts Boston, Boston, MA
Tiffany Moore Simas, MD, MPH, MEd, FACOG, Department of Obstetrics & Gynocology, University of Massachusetts Medical School, Worcester, MA
Heather Harker Ryan, Nursing, University of Massachusetts Boston, Boston, MA
Qi Sun, ScD, Channing Lab, Harvard School of Medicine, Boston, MA
Laura L. Hayman, PhD, RN, FAAN, College of Nursing and Health Sciences, University of Massachusetts-Boston, Boston, MA
Introduction: Prior evidence suggests that phytoestrogens such as soy derived isoflavones may have beneficial effects on cardiovascular health and glycemic control. These data are mainly limited to postmenopausal women and individuals at elevated cardiometabolic risk. Because plasma estrogen concentrations rise during pregnancy and are thought to alter lipid and glucose metabolism, it is important to understand whether soy isoflavones are associated with markers of lipid and glucose metabolism in pregnant women. Methods: We analyzed data from 299 pregnant women who participated the 2001-2008 NHANES for whom 24-hour dietary recall, food frequency questionnaire, urinary isoflavone concentrations, and cardiometabolic risk biomarker measures were available. We examined urinary concentrations of isoflavones and metabolites in relation to cardiometabolic risk markers, adjusted for BMI, pregnancy trimester, total energy intake, and demographic and lifestyle factors. Results: Self-reported soy intake was positively correlated with urinary isoflavone and its metabolite concentrations (r = 0.21, P=0.02 for total isoflavones; r = 0.18, P=0.04 for O-DMA; r = 0.23, P=0.01 for equol). There was a significant, negative relationship between urinary isoflavone concentrations and cardiometabolic risk markers: comparing women in the highest versus lowest quartiles of total isoflavone excretion, multivariate-adjusted fasting glucose concentrations were 79.7 versus 89.8 mg/dL (P for trend=0.001). These figures were 10.3 versus 21.2 μU/mL (P for trend=0.03) for fasting insulin concentrations, and 2.1 versus 5.1 (P for trend=0.03) for HOMA-IR. The associations between isoflavone markers and blood lipid levels did not reach significance level. Discussion: Soy intake may have favorable effects on insulin sensitivity in pregnant women.

Learning Areas:

Chronic disease management and prevention
Public health or related research

Learning Objectives:
Describe in pregnant women the association between urinary isoflavone excretion and their metabolites, including daidzein, genistein, O-desmethylangolensin (O-DMA) and equol, and self-reported soy intake; Analyze in pregnant women the associations of soy isoflavone excretion with plasma lipid concentrations and insulin sensitivity

Keyword(s): Nutrition, Pregnancy

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I have been the principal or co-investigator of multiple funded grants focusing on the dietary factors related to cardiometabolic risks.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.